Family Reported Outcome Measure©--Thai Version

Chantarasap, Pattariya; Pratheepawanit, Nutjaree; Pairojkul, Srivieng; Sookprasert, Aumkhae; Wirasom, Kosin; Cheawchanwattana, Areewan; Salek, Sam; Subongkot, Suphat

doi:10.1037/t72597-000

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[25] Initial development resulted from interviews of family members of patients with 144 different diagnoses across 23 medical specialities, [25,26] and has since been widely validated, demonstrated by high internal consistency (Cronbach's α = 0.80-0.89), and high reproducibility (intraclass correlation = 0.85-0.92) and construct validity, in additional medical conditions, including urological, cancer, COVID-19 and myalgic encephalitis as well as in multiple languages and cultures. [27][28][29][30][31][32][33] Although the FROM-16 is a reliable tool for measuring family impact across a wide range of medical disciplines, it has not yet been applied to a population of ATMP patients and their families, which have some unusual features such as very high treatment costs, often for inherited conditions with others in the family affected but not treated.…”

Section: Family-reported Outcome Measure-16mentioning

confidence: 99%

Validation of the FROM-16 in Family Members of Patients Receiving Advanced Therapy Medicinal Product (ATMP)

Brilliant,

Finlay,

Salek

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: Outcome-based pricing models which consider domains of value not previously considered in healthcare, such as societal outcomes, are of increasing interest for healthcare systems. Societal outcomes can include family-reported outcome measures (FROMs), which measure the impact of disease upon the patient’s family members. The FROM-16 is a generic and easy-to-use family quality of life tool, but it has never been used in the context of patients undergoing advanced therapy medicinal product (ATMP) treatment. The use of potentially curative ATMPs is limited due their high cost and the low number of eligible patients. Using the FROM-16 to collect evidence of family impact in ATMP patients may demonstrate the potential value created by an ATMP intervention. Methods: This feasibility study aimed to test the validity of the FROM-16 in family members of ATMP patients. Patients and family members (n = 24) were recruited from ATMP treatment centres in England and Wales. Family members completed the FROM-16 and were invited to a short debriefing interview. Results: The FROM-16 showed high validity demonstrated by strong internal consistency (Cronbach’s alpha = 0.917) and intraclass correlation (0.803, 95%). Interviews identified that whilst the FROM-16 covered most areas of quality of life impact experienced by the participants, some explained that they also experienced other impacts upon their personal health and future outlook. Conclusion: This feasibility study provides evidence that the FROM-16 could be used as part of a structured systematic approach to measure family quality of life impact in ATMP patients.

show abstract